Thymectomy for non-thymomatous myasthenia gravis: a propensity score matched study by unknown
Barnett et al. Orphanet Journal of Rare Diseases  (2014) 9:214 
DOI 10.1186/s13023-014-0214-5RESEARCH Open AccessThymectomy for non-thymomatous myasthenia
gravis: a propensity score matched study
Carolina Barnett1,2*, Hans D Katzberg1, Shaf Keshavjee3 and Vera Bril1Abstract
Background: The efficacy of thymectomy in patients with non-thymomatous Myasthenia Gravis (MG) is still unclear.
Main limitations have been variable outcome definitions, lack of a control group and adjustment for confounding.
Objective: To study the efficacy of thymectomy in achieving remission or minimal manifestation (R/MM) status in
patients with non-thymomatous MG.
Methods: Patients with generalized MG and minimum follow-up of 6 months were included. Demographic data
and treatments were recorded, as well as the MGFA post-intervention status at the last visit. Propensity scores were
used to create a matched cohort of treated and untreated patients. Standard and Bayesian Cox models were used
to study treatment effects.
Results: Of 395 patients included, 183(46%) had a thymectomy. Thymectomy patients were younger (p < 0.001),
with more females (p < 0.001) and more patients in MGFA classes 4–5 at diagnosis (p = 0.01). A matched cohort of
thymectomized patients and controls (n = 98) was created. The hazard ratio (HR) for the matched cohort was 1.9
(CI:1.6-2.3), favoring thymectomy. The predicted R/MM rate was 21% in treated and 6% in controls at 5 years
(Absolute difference:15%). A Bayesian Cox model for the matched cohort had an estimated probability of
thymectomy efficacy (HR > 1) of 96% using a non-informative prior, and 79% using a skeptical prior.
Discussion: When controlling for potential confounders, thymectomized patients had a higher probability of
achieving R/MM status through time compared to controls. This study provides class III evidence of the efficacy of
thymectomy in non-thymomatous myasthenia gravis.
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The efficacy of thymectomy in improving outcomes in pa-
tients with non-thymomatous myasthenia gravis (MG) is
still under study, despite the fact that it has been used in
clinical practice for over 60 years [1-3]. The evidence of its
efficacy has been based on observational studies with dif-
ferent methodological considerations. For example, differ-
ent definitions of remission have been used and there has
been inconsistent control for confounders. In some cases,
relative risks have been used, when time-to-event analyses
are more appropriate given different follow-up times
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unless otherwise stated.from the American Academy of Neurology in 2000 [7],
that reported a systematic review of the literature and
found that studies controlling for different confounders,
showed conflicting results. The authors concluded that
the evidence supported the use of thymectomy as an
option to improve outcomes, but that further studies and
ideally randomized control trials should be pursued.
In the past years, several case series of thymectomy
have been published, and different surgical techniques
have been studied, but most of those studies have lacked
a control arm and have variable adjustment for con-
founders [8-11]. Even though the surgical management
of MG patients has improved with time and the associ-
ated morbidity and mortality are low, especially with less
invasive techniques [7,8], thymectomy still conveys risks
and associated costs. Therefore, it is imperative to better. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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these patients.
A recent Cochrane review [12] concluded that there is
lack of evidence to support the use of thymectomy in
non-thymomatous MG, and that randomized and quasi-
randomized studies are needed. A randomized control
trial is underway (NCT00294658) [13], but its results are
yet not available. The difficulties in performing such a
trial create the need for well-designed observational
studies to add to the evidence base on this relevant
question.
In our center, thymectomy for non-thymomatous
MG, is usually performed in patients with generalized
MG who are young, and therefore most frequently
women. Given this clear bias by indication, where base-
line characteristics and associated medical treatments
can affect the outcomes, we used propensity scores to
create a matched dataset, thus simulating a randomized
study. The primary objective of this study was to esti-
mate the treatment effect of thymectomy in achieving
remission or minimal manifestation status [as defined by
the Myasthenia Gravis Foundation of America (MGFA)
classification] in patients with non-thymomatous MG. We
hypothesized that thymectomized patients would have a
higher probability of achieving remission or minimal
manifestation status through time compared to controls.
Methods
Data collection
Records from consecutive MG patients who attended
the Neuromuscular Clinic, Toronto General Hospital,
from January 2000 to August 2013, were retrospectively
reviewed. Inclusion criteria were: confirmed generalized
MG and minimal follow-up of 6 months. We excluded
patients with purely ocular disease, thymoma or miss-
ing data on occurrence of thymectomy and/or post-
intervention status. The diagnosis of MG was based on
the clinical presentation and abnormal antibody status
(acetylcholine or muscle specific kinase) or single fiber
electromyography. One assessor collected the demo-
graphic data, including: age at onset, time to diagnosis,
antibody status, medications, thymectomy status (in-
cluding type of thymectomy) and total time of follow-up.
The Myasthenia Gravis Foundation of America (MGFA)
class at diagnosis and MGFA post-intervention status
(PIS) [14] at the last visit, were recorded separately by a
neuromuscular physician (CB). Following the MGFA-PIS
classification, remission was defined as a minimum of
1 year without symptoms (eye closure weakness accepted)
and without pyridostigmine. Asymptomatic patients for at
least a year but using pyridostigmine or patients with min-
imal signs or symptoms (i.e. isolated ptosis) for at least a
year were classified as minimal manifestations. Given the
difficulties of timing relapses retrospectively, these werenot considered, and only the clinical status at the last visit
was used. The primary outcome was the presence of re-
mission or minimal manifestation status (R/MM) accord-
ing to the MGFA-PIS at the last visit. The University
Health Network Research Ethics Board approved this
study.
Statistical analyses
1. Descriptive statistics and missing data: Continuous
variables were expressed by means and SD, and
nominal variables by number of observations and
proportions. Variables with < 20% missing data were
dealt by with multiple imputation. Variables with >
20% missing data were not included in the models.
All analyses were done with R-statistical software
(The R foundation for statistical software, version
3.0.2).
2. Propensity Score (PS) Models: Several models were
tested, and the model with the best balance between
the variables was chosen [15]. All models tested
included the main drivers of the decision to operate
in our center: age and sex. Since these are related,
they were modeled as an interaction. In addition,
several other potential confounders were tested,
alone and in combination, since the incorporation of
other confounders has shown to improve estimates
and balance of PS models [15]. The variables tested
in the models were: time to diagnosis, MGFA status at
diagnosis (I,II,III, and IV-V), and use of prednisone,
azathioprine and mycophenolate mofetil during the
follow-up period. Other medications such as
methotrexate, cyclosporine and rituximab are
infrequently used and were not included in the PS
models, but their balance was tested before and
after matching. IVIG and plasma exchange (PLEX)
are used for worsening disease or crisis, and also
pre-thymectomy, but are not routinely used as
chronic treatment. Therefore, as they are not
expected to affect the likelihood of achieving R/MM
status, we did not include them in the models.
However, we described the proportion of patients
receiving these treatments during follow-up in the
matched cohort.
3. Matching and Balance of the Covariables: Matching
was done in a 1:1 proportion without replacement,
matching on the PS using a nearest-neighbor
algorithm with a caliper of 0.2 [16]. This was done
using the MatchIt package for R [17]. To test for
balance of the different variables on the matched
dataset, we used the absolute standardized difference
(ASD), where values < 0.1 are considered indicators of
appropriate balance. This approach is preferred to the
use of significance testing, since p-values are
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might not be sensitive enough to detect imbalance
[16]. All subsequent analyses on the matched dataset
used frailties or random effects to account for the
paired nature of the data [18].
4. Time-to-event Analyses: The primary outcome was
the hazard ratio (HR) for achieving R/MM status at
the last visit, fitting a Cox model on the matched
dataset. Patients who were not in R/MM at the last
visit were right-censored. Using the survival models
coefficients, we estimated the probability of achieving
R/MM status at 5 years. That time frame was chosen
to detect longer-term effects of treatment, and was
below the mean follow up time ranges for both
groups. As a secondary analysis, a Cox model was
built for the complete, unmatched dataset, adjusting
for all the possible confounders, including age, sex,
medications, time to diagnosis and MGFA class at
baseline. For the secondary outcome, the use of
prednisone at the last visit was modeled in a time-
to-event fashion, whereby the hazard ratio for being
on prednisone (HR) was estimated on the matched
dataset. For all Cox models, the proportional hazard
assumption was tested through the Schoenfield
residuals [19].
5. Bayesian Models: To estimate the probability of
thymectomy effectiveness (probability of HR > 1),
Bayesian proportional hazard models were built for
the matched and unmatched datasets. For each
dataset, we used different prior probabilities as a
form of sensitivity analysis [20]. First, we used non-
informative priors, assuming no previous knowledge
of the role of thymectomy in this population. This
prior had a normal distribution with a log HR mean
of 0 and precision of 10−6. We then used a skeptical
prior, assuming a prior probability of no effect of
thymectomy (HR = 1, neither beneficial nor harmful)
with a 95% CI between 0.6 and 1.4. This last model
placed more strength in the prior probability of no
thymectomy effect, therefore giving more strength
to the null hypothesis [21,22]. For all models, we
assumed a constant hazard rate and therefore we
used an exponential distribution. We used Monte
Carlo Markov Chain (MCMC) simulations with
Gibbs sampling, using JAGS (v.3.0.2) [23] through
the rjags package for R [24]. All models were initiated
with 3 chains. To ensure convergence, 10,000 burn-in
iterations were done, followed by 10,000 samples to
calculate the estimates. Convergence was tested by
visualizing the traces from the 3 chains and by the
Gelman-Rubin statistic. The parameters calculated
were the median estimated HR with 95% Credible
Intervals (CrI), the probability of a HR >1 (in favor of
thymectomy), the median probabilities of achievingR/MM status at 5 years and the median absolute
difference in R/MM status between groups at 5 years.
Results
Patients
395 patients met the inclusion criteria. Of these, 183
(46%) had had a thymectomy. Thymectomized patents
were younger, and had a higher proportion of women (p <
0.001). They also had longer mean follow-up times and
more patients were in MGFA classes IV-V at diagnosis.
Detailed characteristics of both groups are shown in
Table 1. At the last visit, 40(22%) had R/MM status in the
thymectomy and 49(23%) in the control group. In the thy-
mectomized group, data on the operative protocol were
available for 125 patients. Of these, 104 (83%) had a trans-
cervical video assisted thymectomy, 20 (16%) a trans-
sternal thymectomy and 1(1%) both. There were missing
data on time to diagnosis (14.5%) and baseline MGFA
(3%). Data on acetylcholine receptor antibodies were avail-
able for 45% of patients, and thus antibody status was not
included in the models. There were no missing data for
the other variables included in the PS models.
PS matching
The final PS model included the interaction between age
and sex, and also time to diagnosis and MGFA class at
diagnosis. This resulted in a matched dataset with n =
98. This dataset demonstrated adequate balance of all
the covariables (standardized difference <0.1), with only
residual imbalance in the time of follow up (ASD = 0.16).
Table 1 shows the characteristics of the matched dataset
compared to the total cohort. Excluding pre-surgical
treatments, PLEX was given to 12(24%) and 14(28%) of
thymectomy patients and controls respectively (p = ns)
during follow-up. 17(35%) patients received IVIG in the
thymectomy and 23(47%) in the control group (p = ns).
Cox models
In the matched dataset, thymectomized patients had a
higher likelihood of achieving R/MM with time than the
controls (HR: 1.9, CI:1.6, 2.3). In the unmatched dataset,
the adjusted estimated HR was similar, but it did not
reach statistical significance (HR: 1.5, CI:0.8, 2.8). Using
the matched data, the estimated rates of R/MM at 5 years
were 21% (CI:16, 40) for the thymectomy group and 6%
(CI:0–13)for the controls. This yields an absolute differ-
ence of 15% (CI:1, 29), with a NNT = 7. Details of these
results are in Table 2, and Figure 1 represents the cumu-
lative hazards for R/MM status in the matched data.
Regarding the use of prednisone at the last visit, the
thymectomy group was less likely to be on prednisone
than controls (HR: 0.8, CI:0.7-0.95, p = 0.005). At 5 years,
the predicted proportion of patients using prednisone
was 23% in thymectomy patients and 30% in controls.
Table 1 Demographic characteristics of matched and unmatched cohorts













Age (mean ± SD) 34.8 ± 14.1 63.7 ± 12.7* 2.33† 49.8 ± 14.3 50.1 ± 13.2 0.02
Females [n (%)] 124(68) 89(42)* 2.03† 25(51) 27(50) 0.08
Time to Dx (mean ± SD) 14.8 ± 26.1 16.9 ± 31.8 0.55† 17.8 ± 25.6 18.3 ± 27.3 0.02
MGFA class at diagnosis n [(%)]
MGFA I 16(9) 31(15)* 0.21† 5(10) 4(8) 0.07
MGFA II 57(31) 81(38) 0.15† 21(43) 23(47) 0.08
MGFA III 70(38) 73(34) 0.08 17(35) 15(31) 0.08
MGFA IV/V 40(22) 27(13)* 0.22† 6(12) 7(14) 0.05
Medications [n(%)]
Prednisone 130(71) 166(78) 0.16† 35(71) 33(67) 0.09
Azathioprine 109(60) 118(56) 0.08 30(61) 31(63) 0.04
Mycophenolate 32(18) 41(19) 0.05 6(12) 7(14) 0.05
Other immunosupressants 28(15) 21(10) 0.15 4(8) 5(10) 0.07
Follow-up (mean ± SD) 118.9 ± 115.9 67.4 ± 52.8* 0.44† 95.9 ± 103.1 76.4 ± 54.6 0.16†
Continuous data are expressed as median and range.
Nominal data are expressed as number and proportion of patients.
MGFA: Myasthenia Gravis Foundation of America. The proportion of patients in each MGFA class at diagnosis, before treatment, is presented for both groups.
Time to Diagnosis (Dx) and Follow-up are in months.
Other immunosupressants include: methotrexate, rituximab, cyclosporine and cyclophosphamide.
†Absolute Standardized Difference > 0.1, indicating poor balance of the variable between groups.
*p < 0.05. p-values are less sensitive than the Absolute Standardized Difference to detect imbalance.
The matched dataset has excellent balance of all the variables, except mild residual imbalance of follow-up times. This was accounted with time-to-event analyses.
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tion of follow-up time using prednisone and the dose of
prednisone on the last visit for treated and controls.
Bayesian models
Using an uninformative prior, the unmatched data had a
median HR for achieving R/MM status of 1.9 (CrI: 1.0,
3.3), with a 98% probability of having a HR > 1 (favoring
thymectomy); in the matched data, the median HR wasTable 2 Hazard ratios, absolute differences for matched and
HR for R/MM status
Standard Cox models
Unmatched data 1.5 (CI: 0.8, 2.8)
Matched data 1.9 (CI: 1.6, 2.3)*
Bayesian models
Matched data, uninformative prior 2.2 (CrI: 0.9, 6.0)
Matched data, skeptical prior 1.2 (CrI: 0.8, 1.6)
Unmatched data, uninformative prior 1.9 (CrI: 1.0, 3.3)
Unmatched data, skeptical prior 1.2 (CrI: 0.8, 1.7)
Values for the standard Cox models are expressed with a 95% confidence interval (
The Bayesian models used 10000 iterations. The values presented are the median a
HR: Hazard Ratio.
HR > 1 indicates increased likelihood of achieving R/MM, favoring thymectomy.
R/MM: Remission or Minimal Manifestation Status.
*p < 0.0001. p values are not part of Bayesian analyses.2.2 (CrI:0.9, 6.0), with a probability of thymectomy effi-
cacy of 96%. Using a skeptical prior, the median HR was
1.2 (CrI:0.8, 1.6), with a probability of thymectomy effi-
cacy of 79% in the matched data, and 1.2 (CrI: 0.8, 1.7),
with a probability of thymectomy efficacy of 86% in the
unmatched data. Table 2 shows the parameters of the
different Bayesian models, and Figure 3 Shows Bayesian
tri-plots, illustrating the different probabilities (prior,
likelihood and posterior) of thymectomy efficacy in the
matched and unmatched data.unmatched dataset
Absolute difference in R/MM at 5 years Probability HR > 1
−3% (CI: −10, 4) –
15% (CI: 1, 29) –
9% (CrI: −1, 27) 96%
2% (CrI: −1, 9) 79%
20% (CrI: 2, 38) 98%
4% (CrI: −3, 12) 86%
CI).
nd 95% credible intervals (CrI).
Figure 1 Cumulative proportion of remission/MM status in thymectomy and controls, in the matched dataset. Patients who had thymectomy
had a higher likelihood of achieving Remission/MM status through time, compared to controls. (HR:1.9, CI:1.6, 2.3. p < 0.001). The absolute estimated
difference at 5 years (60 months) was 15%.
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In this study, we used novel methods to assess the treat-
ment effect of thymectomy in non-thymomatous myas-
thenia gravis. The use of propensity scores is widespread
in the literature [25], but to our knowledge, it has not
been used before for this clinical question. Further, we
incorporated Bayesian analyses to assess the overall prob-
ability of thymectomy efficacy, which can be easier to
interpret from a clinical perspective. Bayesian methods
allow for incorporating previous knowledge or beliefs.
Since previous data on thymectomy efficacy are inconsist-
ent, we used 2 approaches to estimate our prior possibil-
ities: assuming no knowledge (non-informative prior) and
assuming evidence of no efficacy (skeptical prior). The
first assumption allowed us to place more emphasis in our
observed data, and the second assumption served to
incorporate the “worst case scenario” for thymectomy,
giving more weight to a previous belief of no efficacy [26].
Finding an effect in this skeptical model strengthens our
findings. In addition, Bayesian methods are not limited by
sample size, and that is an asset when studying rare dis-
eases [27] such as MG, and in this particular case of a
matched dataset with a smaller sample size.
We found that thymectomy is associated with a high
probability of achieving remission or minimal manifest-
ation status, when compared to no surgery in patients
with non-thymomatous MG after controlling for several
confounders, including age at onset, time to diagnosis,
MGFA class at diagnosis and the use of several immu-
nosupressants. The different times of follow-up were
accounted for using a time-to event approach. Therefore,
our study follows the recommendations by the AAN prac-
tice parameter [7] and the recommendations for MGresearch issued by the MGFA [28]. For robustness, we
used different models to assess the outcome, including
standard and Bayesian models in both the matched and
unmatched datasets, and the findings were consistent
across models and datasets. Even when using a skeptical
model, the probability of efficacy remained high. The
absolute difference estimates for R/MM rates at 5 years
between treatment groups ranged between 2% in the
skeptical Bayesian model with matched data to 20% in the
uninformative Bayesian model with unmatched data. A
relevant question that arises from these findings is how
big should the treatment effect be (i.e. absolute difference)
to be significant from a clinical and cost-effective perspec-
tive. Future cost-effectiveness studies incorporating the re-
sults from the ongoing RCT will be needed to answer that
question. In addition, as secondary outcome, we found
that thymectomy was also associated with a higher likeli-
hood of being free from prednisone through time. This is
of relevance, given the known secondary side effects of
long-term steroid use, and the documented correlation
between prednisone use (especially high dose) and re-
duced quality of life in MG patients [29].
We found a low rate of remission (10%) compared to
previously published thymectomy studies, and therefore,
we included minimal manifestation status in the primary
outcome for statistical considerations. Minimal manifest-
ation includes patients who have been asymptomatic for
at least a year but are using pyridostigmine, as well as
patients with minimal symptoms such as isolated ptosis.
Therefore, we considered it as a good clinical outcome.
The relatively low rate of remission might be explained
by several factors: firstly, we used the MGFA-PIS classifi-
cation, that requires at least 1 year without symptoms
Figure 2 Relationship between prednisone treatment duration
and dose of prednisone on the last visit in the matched cohort.
The overall use of prednisone through time is presented as a ratio
of the time under prednisone in months, over the total follow-up
time, to account for different follow times. Patients with higher
ratios of prednisone use through time were more likely to have
higher doses at the last visit (r = 0.5, p < 0.001) for both groups.
There was no significant difference between groups, although
controls tended to have higher doses of prednisone at the last
visit (p = ns).
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assessing thymectomy have used variable definitions of
remission, with variable lengths of time, and this might
explain some of the differences. Secondly, our data is
from a single, academic referral center. It is possible
that milder cases are being followed at community
hospitals, possibly translating into a cohort of more se-
verely affected patients in this study. Therefore, our
findings can only be generalized to similar clinical
settings. Additionally, we excluded patients with very
short follow-up times. This is because our aim was to
look at the longer-term effect of thymectomy. Even though
there are some reports of early improvement after surgery,
an effect of pre-surgical IVIG or PLEX can’t be ruled out;
therefore we excluded those cases from our cohort.
The use of observational data has advantages and limi-
tations. Observational studies are typically more feasible
than RCTs, which are costly and hard to implement for
several reasons, and so far, only one RCT addressing
this question is on course. RCTs provide some of the
strongest evidence by balancing confounder factors bydefault and prospectively collecting data. However, the
inclusion criteria are usually more restrictive, affecting
the generalizability of the results. In that sense, obser-
vational data can be more pragmatic, because they can
better represent the “real world” of patients with dif-
ferent characteristics and treatments that often make
them not eligible for RCTs. However, confounding is
always a concern in observational studies, therefore the
need for rigorous data collection and analysis. We eagerly
await the results of the ongoing RCT, but we believe that
further studies on prospectively collected observational
data are also required, since it is unlikely that another
RCT addressing this question will be carried in the future.
This study is not without limitations. Propensity
scores can only adjust for the known variables, as op-
posed to RCTs were the unknown variables are as-
sumed to be balanced by the randomization. In our
study, the main unknown is the Acetylcholine receptor
antibody status, as this test is not covered by the
Ontario Health Insurance Plan, and thus, many patients
with a confirmed MG diagnosis (based on clinical and
electrodiagnostic criteria) are not tested. Therefore, our
findings might be different to a population of only sero-
positive patients, who could in theory have better re-
sponse to thymectomy [30]. In addition, most of our
patients underwent transcervical video assisted thymec-
tomy, and it is possible that the treatment estimates differ
from other surgical techniques. The transcervical proced-
ure is less invasive and some authors consider that less in-
vasive techniques might result in residual thymic tissue
and therefore might be less effective than trans-sternal
surgery [3]. However, we still found a positive effect with a
predominance of transcervical thymectomy, supporting its
use. A matched study comparing different surgical ap-
proaches can answer whether there is different efficacy
with different surgical techniques, and also compare
complications and associated costs.
The retrospective data collection is another potential
source of bias. Even though data on the use of immu-
nosupressants were available for all patients as a di-
chotomous variable (yes/no), we could not capture the
different doses through time, which could influence the
outcome. We tried to maintain blinding by having dif-
ferent assessors capture the demographic and the out-
come data. However, given the retrospective review,
blinding was not always maintained and that could have
introduced bias. A prospective study, with dynamic col-
lection of medications and doses, could provide more
accurate treatment effects, modeling the immunosup-
pressant data as time-dependent covariables, and ensur-
ing blinding assessment of outcomes. In the case of
prednisone, prospectively collecting data can also allow
for estimating the cumulative use of prednisone
through time, which can be an important outcome.
Figure 3 Bayesian tri-plots of the efficacy of thymectomy using different prior probabilities in the matched and unmatched datasets.
In Figure 3A and B, the blue line depicts the skeptical prior, assuming prior belief of no efficacy of thymectomy, with a mean HR = 1 and 95%
CI:0.6 -1.4. The green line depicts the likelihood, which is the probability of thymectomy efficacy for each model, using the observed data only
(uninformative prior). The red line reflects the posterior probability, which incorporates the prior belief to the likelihood. Figure 3A shows the
probabilities for the matched dataset. The likelihood has a 96% probability of thymectomy efficacy (HR >1), with a posterior probability of 79% after
incorporating the skeptical prior. Figure 3B reflects the unmatched dataset. The likelihood has a 98% probability of thymectomy efficacy, with
a posterior probability of 86% after incorporating the skeptical prior.
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relapse rate in patients achieving remission, which we
did not include in this study.
Conclusion
In summary, using novel statistical techniques in obser-
vational data, we found that thymectomy is associatedwith a high probability of achieving remission or min-
imal manifestation status and of being free from pred-
nisone when compared to controls. Further prospective
studies are needed, and if the evidence of thymectomy
benefit holds, cost-effectiveness studies will be important
in the future to increase our understanding of its role in
the management of MG patients.
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